Litak is a solution for injection that contains the active substance cladribine to treat some forms of leukemia or lymphoma.

Litak was granted the Orphan Drug Status for the treatment of indolent Non-Hodgkin’s lymphoma by the European Agency EMA  in 2001.

In 2013, cladribine received the EMA Orphan Drug Status for the treatment of mastocytosis.

Litak can be used intravenously and as a subcutaneous bolus injection.